Mitch Raponi - Veridex, LLC, a Johnson and Johnson company

基本信息

浏览量：133

职业迁徙

个人简介

Mitch Raponi currently works at BeiGene and does research in Oncology and Translational Diagnostics. His most recent publication is 'Abstract LB-B03: Exosome-based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients.'

研究兴趣

论文共 128 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Table 3 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities Via NAD+ Depletion

Katelyn J. Noronha,Karlie N. Lucas,Sateja Paradkar,Joseph Edmonds,Sam Friedman,Matthew A. Murray,Samantha Liu,Dipti P. Sajed,Chana Sachs,Josh Spurrier,Mitch Raponi,Jiayu Liang,Hao Zeng,Ranjini K. Sundaram,Brian Shuch,Juan C. Vasquez,Ranjit S. Bindra

crossref（2024）

引用0浏览0引用

Supplementary Figure 1 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities Via NAD+ Depletion

crossref（2024）

引用0浏览0引用

Supplementary Figure 11 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities Via NAD+ Depletion

crossref（2024）

引用0浏览0引用

Supplementary Figure 10 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities Via NAD+ Depletion

crossref（2024）

引用0浏览0引用

Supplementary Table 7 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities Via NAD+ Depletion

crossref（2024）

引用0浏览0引用

Supplementary Table 2 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities Via NAD+ Depletion

crossref（2024）

引用0浏览0引用

Supplementary Table 5 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities Via NAD+ Depletion

crossref（2024）

引用0浏览0引用

Supplementary Figure 4 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities Via NAD+ Depletion

crossref（2024）

引用0浏览0引用

Supplementary Figure 2 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities Via NAD+ Depletion

crossref（2024）

引用0浏览0引用

Supplementary Figure 9 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities Via NAD+ Depletion

crossref（2024）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn